Physician profile
John L Hoffman
NPI 1871604520
$2,605.34
in general payments reported to CMS, 2019-2025
29 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $564 · 2021: $296 · 2022: $175 · 2023: $147 · 2024: $238 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.65 | 2019-2021 | |
| Novo Nordisk INC | $271.46 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $269.23 | 2019-2021 | |
| Lilly USA, LLC | $154.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $129.50 | 2019 | |
| Averitas Pharma INC. | $124.99 | 2024 | Qutenza |
| Pfizer INC. | $123.92 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $123.55 | 2019-2020 | |
| Inspire Medical Systems, INC. | $120.54 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $113.33 | 2019-2024 | |
| Ucb, INC. | $84.83 | 2019-2021 | |
| Celgene Corporation | $84.70 | 2019 | |
| Astellas Pharma US INC | $77.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $62.54 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.12 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.27 | 2019 | |
| Janssen Biotech, INC. | $44.29 | 2019-2020 | |
| Genzyme Corporation | $41.32 | 2019 | |
| Gilead Sciences, INC. | $41.02 | 2019 | |
| Daiichi Sankyo INC. | $34.86 | 2021-2023 | Injectafer |
| Vanda Pharmaceuticals INC. | $34.75 | 2021 | |
| Sanofi Pasteur INC. | $34.38 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.10 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $21.09 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.42 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.87 | 2019 | |
| Amarin Pharma, INC. | $13.81 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.